/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | APVOAptevo Therapeutics |
|---|---|
| Last close | $1.13close 2026-11-09 |
| Change % | -8.87%close 2026-11-09 |
| Market cap | $2Mclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $3M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As ofFY ending 2022-12-31 Filing10-K · 0000950170-24-025428 · filed 2024-03-05 Open the filing on EDGAR → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | -74.7%FY to 2022-12-31, older period |
| Net income | $-25967000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-126278 · filed 2026-03-26 Open the filing on EDGAR →Open the XBRL payload →CiteAptevo Therapeutics Inc. (APVO), us-gaap:NetIncomeLoss: -25,967,000 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-126278, filed 2026-03-26. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001671584/us-gaap/NetIncomeLoss.json |
| Net margin | periods differ |
| EPS (diluted) | $-87.27⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-126278 · filed 2026-03-26 Open the filing on EDGAR →Open the XBRL payload →CiteAptevo Therapeutics Inc. (APVO), us-gaap:EarningsPerShareDiluted: -87.27 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-126278, filed 2026-03-26. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001671584/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 4FY to 2022-12-31, older period |
| Altman Z-ScoreUNVALIDATED | -10.37FY to 2022-12-31, older period |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | open now |